Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (2.3), the stock would be worth NT$44.62 (30% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | NT$34.2 |
0%
|
| 3-Year Average | 2.3 | NT$44.62 |
+30%
|
| 5-Year Average | 2.2 | NT$42.79 |
+25%
|
| Industry Average | 2.1 | NT$42.04 |
+23%
|
| Country Average | 2.1 | NT$42.16 |
+23%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
N
|
Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
|
3.5B TWD | 1.7 | 14.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 13.1 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 5.9 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 5.2 | 27.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 5.1 | 19.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 4.7 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 3.2 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 3.1 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.1 |
| 70th Percentile | 3.6 |
| Max | 385 201.6 |
Other Multiples
Nang Kuang Pharmaceutical Co Ltd
Glance View
Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacture, process, and sale of western medicine and medical equipment. The company is headquartered in Tainan, Tainan. The company went IPO on 2005-06-10. The firm main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The firm is also engaged in the manufacture, processing and trading of medical equipment. The firm distributes its products within the domestic market and to overseas markets.
